康泰生物
(300601)
| 流通市值：128.57亿 | | | 总市值：159.50亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 169,306,957.52 | 257,299,273.36 | 1,123,109,043.92 | 216,201,021.06 |
| 交易性金融资产 | 1,711,429,779.45 | 1,688,805,102.78 | 527,400,900 | 30,058,300 |
| 应收票据及应收账款 | 2,752,419,009.27 | 2,583,739,375.47 | 2,826,265,882.01 | 2,913,497,715.05 |
| 其中：应收票据 | 357,853.43 | 0 | - | - |
| 应收账款 | 2,752,061,155.84 | 2,583,739,375.47 | 2,826,265,882.01 | 2,913,497,715.05 |
| 预付款项 | 56,837,275.62 | 21,330,313.78 | 27,810,938.82 | 17,238,756.21 |
| 其他应收款合计 | 11,428,741.37 | 11,159,660.73 | 7,279,819.78 | 9,665,759.08 |
| 存货 | 693,727,506.55 | 681,092,789.35 | 630,237,169.62 | 679,581,268.84 |
| 其他流动资产 | 561,438,256.18 | 751,304,870.09 | 1,070,462,276.84 | 2,224,776,127.33 |
| 流动资产合计 | 5,956,587,525.96 | 5,994,731,385.56 | 6,212,566,030.99 | 6,091,018,947.57 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 1 | 1 | 1 | 1 |
| 投资性房地产 | 774,703,643.74 | 781,430,335.92 | 766,527,224.52 | 773,040,611.91 |
| 固定资产 | 4,315,720,162.56 | 4,253,398,683.13 | 4,230,960,200.72 | 4,132,994,765.56 |
| 在建工程 | 552,271,519.87 | 711,428,973.14 | 783,786,973.08 | 959,925,440.54 |
| 无形资产 | 497,264,162.1 | 467,900,623.1 | 475,609,881.31 | 415,053,694.91 |
| 开发支出 | 100,079,490.69 | 117,488,432.7 | 75,278,108.3 | 134,453,102.09 |
| 长期待摊费用 | 177,906,032.7 | 181,710,689.56 | 142,935,399.31 | 148,011,021.76 |
| 递延所得税资产 | 683,151,952.05 | 689,490,151.04 | 744,190,540.51 | 732,933,317.78 |
| 其他非流动资产 | 928,731,666.64 | 897,839,141.71 | 702,472,160.54 | 741,493,899.77 |
| 非流动资产合计 | 8,029,828,631.35 | 8,100,687,031.3 | 7,921,760,489.29 | 8,037,905,855.32 |
| 资产总计 | 13,986,416,157.31 | 14,095,418,416.86 | 14,134,326,520.28 | 14,128,924,802.89 |
| 流动负债: | | | | |
| 短期借款 | 11,005,157.78 | 0 | 14,400,000 | 39,900,000 |
| 应付票据及应付账款 | 571,064,424.06 | 708,248,201.19 | 709,596,042.29 | 704,585,457.7 |
| 其中：应付票据 | 48,601,852.44 | 116,399,324.35 | 154,280,925.92 | 142,496,467.9 |
| 应付账款 | 522,462,571.62 | 591,848,876.84 | 555,315,116.37 | 562,088,989.8 |
| 预收款项 | 7,377,647.21 | 8,622,552.16 | 8,777,882.48 | 3,257,617.78 |
| 合同负债 | 24,603,694.25 | 32,239,935.86 | 33,466,178.19 | 18,159,321.93 |
| 应付职工薪酬 | 54,065,828.45 | 55,133,950.36 | 30,177,978.31 | 31,542,317.48 |
| 应交税费 | 17,618,539.46 | 11,108,797.72 | 17,133,230.38 | 18,297,706.41 |
| 其他应付款合计 | 1,360,437,740.97 | 1,382,713,747.97 | 1,478,248,351.51 | 1,442,636,970.87 |
| 一年内到期的非流动负债 | 25,532,248.65 | 16,660,078.92 | 7,590,687.46 | 28,173,926.67 |
| 其他流动负债 | 3,148,313.92 | 957,071.16 | 1,040,217.45 | 530,369.37 |
| 流动负债合计 | 2,074,853,594.75 | 2,215,684,335.34 | 2,300,430,568.07 | 2,287,083,688.21 |
| 非流动负债: | | | | |
| 应付债券 | 1,890,333,837.48 | 1,869,842,009.68 | 1,848,892,938.38 | 1,828,502,013.3 |
| 预计负债 | 97,102,444.6 | 115,418,425.24 | 109,174,933.64 | 143,120,378.89 |
| 递延收益 | 258,296,638.08 | 262,213,774.52 | 234,111,073.32 | 240,094,075.8 |
| 递延所得税负债 | 671,670.57 | 671,670.57 | 31,201,827.64 | 31,201,827.64 |
| 非流动负债合计 | 2,246,404,590.73 | 2,248,145,880.01 | 2,223,380,772.98 | 2,242,918,295.63 |
| 负债合计 | 4,321,258,185.48 | 4,463,830,215.35 | 4,523,811,341.05 | 4,530,001,983.84 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,116,929,755 | 1,116,929,375 | 1,116,929,111 | 1,116,928,537 |
| 其他权益工具 | 511,037,083.03 | 511,038,616.92 | 511,039,690.65 | 511,042,017.06 |
| 资本公积 | 5,511,665,861.23 | 5,511,659,067.57 | 5,511,654,387.54 | 5,511,644,315.26 |
| 其他综合收益 | -242,690.87 | -206,750.32 | -184,312.66 | -186,905.8 |
| 盈余公积 | 364,998,253.51 | 364,998,253.51 | 347,128,374.64 | 347,128,374.64 |
| 未分配利润 | 2,160,663,751.3 | 2,127,324,728.65 | 2,124,021,818.17 | 2,112,396,887.74 |
| 归属于母公司股东权益合计 | 9,665,052,013.2 | 9,631,743,291.33 | 9,610,589,069.34 | 9,598,953,225.9 |
| 少数股东权益 | 105,958.63 | -155,089.82 | -73,890.11 | -30,406.85 |
| 股东权益合计 | 9,665,157,971.83 | 9,631,588,201.51 | 9,610,515,179.23 | 9,598,922,819.05 |
| 负债和股东权益合计 | 13,986,416,157.31 | 14,095,418,416.86 | 14,134,326,520.28 | 14,128,924,802.89 |
| 公告日期 | 2026-04-22 | 2026-04-22 | 2025-10-28 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |